BME100 f2014:Group19 L2

From OpenWetWare
Jump to: navigation, search
Owwnotebook icon.png BME 100 Fall 2014 Home
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help
BME494 Asu logo.png


Name: Andrew Carlson
Name: Stacy Stoddard
Name: Gareth Palas
Name: Josh Hislop
Name: Josh Martin
Name: Jose Elenes


Descriptive Statistics

Human Experiment
human inflammotin table human inflammotin graph

Rat Experiment
rat inflammotin table rat inflammotin graph

Inferential Statistics

Human Experiment
human inflammotin anova

Since there were more than two trial groups in the human experiment, we used the ANOVA test to compare the statistical difference.



We performed a Post-Anova Test because each LPS-dosage needs to be compared to each other before it can be determined if the data is statistically significant. The alpha value (.05) is divided by the number of each comparison. And so, all the p-values need to be less than the new given alpha value:


Since all the p-values of each comparison were less than the new alpha value, then there is a statistical difference in the inflammotin levels!

Rat Experiment

rat inflammotin t-test

Since there were only two trial groups in the rat experiment, we used the T-Test to compare the statistical difference.


Human Experiment
Based on the p-value (1.4e-16) from the ANOVA test, we can conclude that the human trials had statistically significant differences in Inflammotin levels when given different dosages of LPS.

Rat experiment
The result of the T-test of the data collected from the rat experiment indicates that there is no statistically significant difference between the group of rats treated with inflammotin and those that were not. This result was expected; the raw data displayed similar values (and similar Inflammotin variation) over both tested groups. The test value reflects this; a p-value of .86 greatly exceeds the required .05 experimental value.


As the dosages of LPS increased throughout the human trials, there was a significant change in the amount of inflammotin protein. As shown by the averages in the graph, the inflammotin levels significantly increase as the dosage levels get bigger especially between the 5mg dose and the 10mg dose.However, as the dosage increases, the standard deviation also increases significantly. This is evidence that the drug affects each person differently especial as the dose of LPS reaches 10mg and 15mg.

In the rat experiment through the t-test it was found that there is no statistical difference between the two dosages tested in the experiment. As shown by the graph, as the dosage of LPS went up, there was no real change in the amount of inflammotin protein. The slight increase of the higher dosage is due to an outlier in the data, which explains the high standard deviation in the data corresponding to the 10mg dose.

In the human trial there is a statistical difference between the dosages of LPS and human inflammotin, while in the rat trials there is not a statistical difference between the two dosages of LPS and rat inflammotin. Therefore, it can be concluded that LPS has no effect in inflammotin protein production in rats, only in humans. LPS only produces the desired effect in the human body.